PapastergiouJAbdallahMTranAFolkinsC. Domperidone withdrawal in a breastfeeding woman. Can Pharm J (Ott)2013;146:210-2.
2.
LaduronPMLeysenJE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol1979;28:2161-5.
3.
BaroneJA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother1999;33:429-40.
4.
SchinkelAHWagenaarEMolCAAMvan DeemterL. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest1996;97:2517-24.
5.
TsujikawaKDanYNagawaK. Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharm Drug Dispos2003;24:105-14.
6.
EkCJDziegielewskaKMHabgoodMDSaundersNR. Barriers in the developing brain and neurotoxicology. Neurotoxicology2012;33:586-604.
7.
WarrenMSZerangueHWoodfordK. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells in five species including human. Pharmacol Res2009;59:404-13.
8.
TamaiITsujiA. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci2000;89:1371-88.
9.
SeeligA. The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J Mol Neurosci2007;33:32-41.
10.
EyalSHsiaoPUnadkatD. Drug interactions at the blood-brain barrier: fact or fantasy?Pharmacol Ther2009;123:80-104.
11.
KnoppertDCPageAWarrenJ. The effect of two different domperidone doses on maternal milk production. J Hum Lact2013;29:38-44.
12.
RaiaJJBaroneJAByerlyWG. Determination of steady-state dose proportionality of domperidone in healthy volunteers. Pharmacotherapy1990;10:252.
13.
HuffRMMolinoffPB. Quantitative determination of dopamine receptor subtypes not linked to activation of adenylate cyclase in rat striatum. Proc Natl Acad Sci U S A1982;79:7561-5.
14.
LazarenoSNahorskiSR. Selective labelling of dopamine (D2) receptors in rat striatum by [3H]domperidone but not by [3H]spiperone. Eur J Pharmacol1982;81:273-85.
15.
RosenfeldMRDvorkinBKleinPNMakmanMH. Differential affinities of molindone, metoclopramide and domperidone for classes of [3H]spiroperidol binding sites in rat striatum: evidence for pharmacologically distinct classes of receptors. Brain Res1982;235:205-11.
16.
RzezniczakHWGundlacchALBeartPM. Labelling of high (D-2 receptor) and low affinity sites by [3H]domperidone in homogenates of the corpus striatum of the rat. Neurosci Lett1982;30:63-8.
17.
SeemanPTallericoTKoF. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: implications for human positron emission tomography. Synapse2003;49:209-15.
18.
SeemanP. Dopamine D2 high receptors on intact cells. Synapse2008;62:314-8.
MadrasBK. History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia. J Hist Neurosci2013;22:62-78.
21.
LevantBGrigoriadisDEDe SouzaEB. Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors. Eur J Pharmacol1995;278:243-7.
22.
NakajimaSGerretsenPTakeuchiH. The potential role of dopamine D3 receptor neurotransmission in cognition. Eur Neuropsychopharmacol2013;23:799-813.
23.
SeemanP. Schizophrenia and dopamine receptors. Eur Neuropsychopharmacol2013;23:999-1009.
24.
GardnerDBaldessariniRJWaraichP. Modern antipsychotic drugs: a critical overview. CMAJ2005;172:1703-11.
25.
MoncrieffJ. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand2006;114:3-13.
26.
GoudieAJColeJC. Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications. J Psychopharmacol2008;22:815-7.
